{"id":"NCT01058096","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Cariprazine for Mania","officialTitle":"A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2010-01-28","resultsPosted":"2017-04-17","lastUpdate":"2017-04-17"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder","Mania"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cariprazine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3","timeFrame":"Baseline, Week 3","effectByArm":[{"arm":"Placebo","deltaMin":-15.3,"sd":0.9},{"arm":"Cariprazine","deltaMin":-19.6,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":28,"countries":["United States","India"]},"refs":{"pmids":["31344528","29017067"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":154},"commonTop":["Akathisia","Headache","Tremor","Extrapyramidal Disorder","Nausea"]}}